Welcome to our dedicated page for Alexion Pharms news (Ticker: ALXN), a resource for investors and traders seeking the latest updates and insights on Alexion Pharms stock.
Alexion Pharmaceuticals, Inc. (ALXN) generates frequent news flow related to rare diseases, complement inhibition and ultra-rare metabolic disorders. As a global biopharmaceutical company focused on the discovery, development and commercialization of medicines for devastating conditions, Alexion regularly reports clinical data, regulatory milestones and corporate developments that are relevant to investors, clinicians and patients.
News about Alexion often highlights results from clinical trials of its complement inhibitors in diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG). The company has announced Phase 3 data showing statistically significant improvements in patient-reported and physician-assessed outcomes in gMG, as well as long-term safety and efficacy findings in PNH. Updates from major scientific meetings, including the European Hematology Association Congress and the American Academy of Neurology annual meeting, provide additional detail on how these therapies perform in both clinical trial and real-world settings.
Alexion’s news flow also covers enzyme replacement therapies for hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D), and the use of a Factor Xa inhibitor reversal agent in acute care. Pipeline updates describe progress on mid-to-late-stage programs such as a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and oral Factor D inhibitors, as well as early-stage work in conditions like light chain (AL) amyloidosis.
Corporate announcements, including the definitive agreement for AstraZeneca to acquire Alexion, add another dimension to the news landscape. Readers following ALXN news can expect coverage of clinical trial readouts, regulatory decisions, collaborations, scientific presentations and transaction-related updates. This mix of medical, scientific and corporate information helps market participants understand how Alexion’s rare disease portfolio and pipeline are evolving over time.
Resolution Therapeutics has strengthened its leadership team with two key appointments: Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer. The appointments follow the successful dosing of the first patient in the company's Phase I/II EMERALD study.
Lucy Singah brings over 20 years of corporate and strategic finance experience from companies including Echopoint Medical, GSK, and EY. Daniel Kennedy, with more than 20 years of business development experience, joins from Immunocore (NASDAQ: IMCR) and previously led deals at Achillion Pharmaceuticals, including its $930 million acquisition by Alexion.
The company will host an R&D Webinar on September 17, 2025, featuring clinical hepatologists to discuss its regenerative macrophage therapy (RMT) platform for inflammatory and fibrotic diseases.
Alexion Pharmaceuticals (NASDAQ:ALXN) reported positive topline results from a Phase 3 study of ULTOMIRIS (ravulizumab-cwvz) for adults with generalized myasthenia gravis (gMG). The study achieved statistical significance in its primary endpoint, showing improvement in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score at Week 26, with effects maintained through 52 weeks in the extension study. ULTOMIRIS demonstrated a favorable safety profile and is expected to be submitted for regulatory approval in the U.S., EU, and Japan by early 2022.
Caelum Biosciences and Alexion Pharmaceuticals (NASDAQ:ALXN) announced new Phase 2 data for CAEL-101, a potential first-in-class therapy for AL amyloidosis, presented at the EHA Congress 2021. The data supports the safety and tolerability of CAEL-101 in combination with standard therapies, with findings suggesting cardiac and renal response improvements. The ongoing Phase 3 CARES program aims to enroll approximately 370 patients globally to further evaluate CAEL-101's efficacy in treating this severe disease.
Alexion Pharmaceuticals (NASDAQ:ALXN) announced that the FDA has approved an expanded use of ULTOMIRIS (ravulizumab-cwvz) for children and adolescents with paroxysmal nocturnal hemoglobinuria (PNH). This makes ULTOMIRIS the first FDA-approved treatment for this condition in younger patients. The approval is based on favorable interim Phase 3 study results, showing effective C5 complement inhibition without severe adverse effects. ULTOMIRIS has been the standard of care for adults with PNH since 2018 and is expected to significantly improve the quality of life for affected children.
Caelum Biosciences and Alexion Pharmaceuticals (NASDAQ:ALXN) announced the acceptance of two abstracts on CAEL-101 for e-poster presentation at the European Hematology Association (EHA) Congress 2021, scheduled from June 9 to 17, 2021. The abstracts will present new data from the Phase 2 study of CAEL-101 for AL amyloidosis, highlighting safety and tolerability in combination with standard therapy. The Phase 3 CARES program is underway, aiming to enroll approximately 370 patients globally. CAEL-101 is a first-in-class therapy potentially improving organ function by addressing amyloid deposits.
Alexion Pharmaceuticals (NASDAQ:ALXN) announced the acceptance of five abstracts for the 26th European Hematology Association (EHA) virtual Congress from June 9-17, 2021. Key highlights include data on the long-term safety of ULTOMIRIS® (ravulizumab-cwvz) in PNH patients, showing reduced thrombotic risk. New Phase 3 interim analysis data will also be presented for pediatric patients. The FDA has given priority review for ULTOMIRIS in this demographic with a PDUFA date of June 7, 2021. Presentations will be available online starting June 11, 2021.
Summary not available.
Alexion Pharmaceuticals (NASDAQ:ALXN) reported Q1 2021 revenues of $1,636.5 million, a 13% increase from Q1 2020. Diluted EPS rose 14% to $2.86 on a GAAP basis. Key products showed growth: ULTOMIRIS sales surged 56% to $346.9 million, while STRENSIQ and KANUMA sales grew 15% and 30% respectively. R&D expenses increased to $289.1 million. The company is advancing multiple clinical trials, including ULTOMIRIS in various conditions and plans for new formulations. Upcoming regulatory approvals could further impact growth.
Alexion Pharmaceuticals (Nasdaq: ALXN) will release its financial results for Q1 2021 on April 30, 2021, ahead of the previously stated May 3 date. The company, set to be acquired by AstraZeneca, will not hold a conference call; instead, it will publish earnings materials on its Investor Relations page. The acquisition agreement, announced on December 12, 2020, includes $60 in cash and 2.1243 AstraZeneca ADSs per Alexion share, totaling approximately $39 billion. The transaction is subject to regulatory approval and is expected to close in Q3 2021.
Alexion Pharmaceuticals (Nasdaq: ALXN) will release its first-quarter financial results for 2021 on May 3, 2021, before US markets open. Due to its acquisition agreement with AstraZeneca, no conference call will be held. Shareholders will receive $60 in cash and 2.1243 AstraZeneca ADSs per share, amounting to a total consideration of $39 billion. The acquisition aims to enhance both companies' capabilities in developing innovative medicines and is expected to close in Q3 2021, subject to regulatory approvals.